Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA

[1]  M. Pocard,et al.  Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study , 2022, Annals of Surgical Oncology.

[2]  A. Nissan,et al.  Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[3]  M. Fakih,et al.  PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial , 2021, Annals of Surgical Oncology.

[4]  R. Cavalli,et al.  A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis , 2021, Cancers.

[5]  M. Pocard,et al.  Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. , 2021, The Lancet. Oncology.

[6]  J. Raoul,et al.  A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers. , 2020, European journal of cancer.

[7]  S. Groshen,et al.  Model of a Queuing Approach for Patient Accrual in Phase 1 Oncology Studies , 2020, JAMA network open.

[8]  R. Beets-Tan,et al.  Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis , 2020, European Radiology.

[9]  J. Fontaine,et al.  Prognostic impact of combined progression index based on peritoneal grading regression score and peritoneal cytology in peritoneal metastasis , 2020, Histopathology.

[10]  G. Nadiradze,et al.  Overcoming Drug Resistance by Taking Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) , 2019, Cancers.

[11]  M. Pocard,et al.  Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: A multicenter study. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[12]  D. Bartlett,et al.  Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin , 2019, Annals of Surgical Oncology.

[13]  C. Sempoux,et al.  Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis , 2019, Histopathology.

[14]  M. Pocard,et al.  Pleura and Peritoneum , 2018 .

[15]  Ibrahim Ali,et al.  Experimental pharmacokinetics evaluation of chemotherapy delivery by PIPAC for colon cancer: first evidence for efficacy , 2017, Pleura and peritoneum.

[16]  C. Tournigand,et al.  Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. , 2016, The Lancet. Oncology.

[17]  V. Lemmens,et al.  Bevacizumab in Addition to Palliative Chemotherapy for Patients With Peritoneal Carcinomatosis of Colorectal Origin: A Nationwide Population-Based Study. , 2016, Clinical colorectal cancer.

[18]  C. Sempoux,et al.  Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS) , 2016, Pleura and peritoneum.

[19]  Urs Giger-Pabst,et al.  Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy , 2013, Annals of Surgical Oncology.

[20]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[21]  D. Sargent,et al.  Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Rengo,et al.  Diagnostic performance of computed tomography and magnetic resonance imaging for detecting peritoneal metastases: systematic review and meta-analysis , 2016, La radiologia medica.